Cubist Systematic Strategies, LLC Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Cubist Systematic Strategies, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$233.81 - $287.01 $11.6 Million - $14.3 Million	-49,800 Reduced 97.46%	1,300 $357,000
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $4.3 Million - $7.41 Million	30,000 Added 142.18%	51,100 $12.4 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $644,644 - $872,080	4,400 Added 26.35%	21,100 $3.15 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $151,410 - $196,570	1,000 Added 6.37%	16,700 $3.2 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $153,693 - $190,485	-900 Reduced 5.42%	15,700 $2.78 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $474,916 - $612,378	2,600 Added 18.57%	16,600 $3.33 Million
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $2.6 Million - $3.38 Million	14,000 New	14,000 $3.33 Million

643

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.